The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?-Reference-Cited by-同舟云学术

The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?

Published:2021-02-01 Issue:3 Volume:30 Page:119-127
ISSN:1547-3287
Container-title:Stem Cells and Development
language:en
Short-container-title:Stem Cells and Development

Author:

Khoury Maroun¹²,Ikonomou Laertis³,Dominici Massimo⁴,LeBlanc Katarina⁵,Levine Bruce L.⁶,Weiss Daniel J.⁷

Affiliation:

1. Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile.

2. Cells for Cells and Consorcio Regenero, Chilean Consortium for Regenerative Medicine, Santiago, Chile.

3. Department of Oral Biology, The State University of New York, Buffalo, New York, USA.

4. Division of Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy.

5. Department of Laboratory Medicine, Karolinska Institutet, CAST, Patient Area Cell Therapies and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden.

6. Center for Cellular Immunotherapies, Department of Pathology and Laboratory Medicine, and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

7. Department of Medicine, University of Vermont, Burlington, Vermont, USA.

Publisher

Mary Ann Liebert Inc

Subject

Cell Biology,Developmental Biology,Hematology

Link

https://www.liebertpub.com/doi/pdf/10.1089/scd.2020.0122

Reference17 articles.

1. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19

2. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

3. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

4. Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19

5. Prospects and progress in cell therapy for acute respiratory distress syndrome

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims;Stem Cell Reports;2023-11

2. Expediting Molecular Translational Approach of Mesenchymal Stem Cells in COVID-19 Treatment;Current Stem Cell Research & Therapy;2023-07

3. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery;Frontiers in Immunology;2023-06-21

4. Education for the translation of Advanced Therapy Medicinal Products;Frontiers in Medicine;2023-04-04

5. An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registry;Cytotherapy;2022-11